Sage Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform and cut its price target from $10 to $4.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics' stock is experiencing a decline following a downgrade by RBC Capital from Sector Perform to Underperform, with a price target reduction from $10 to $4.
October 04, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics' stock is trading lower due to RBC Capital's downgrade from Sector Perform to Underperform, with a significant price target cut from $10 to $4.
The downgrade by RBC Capital is a strong negative signal for investors, indicating a lack of confidence in Sage Therapeutics' near-term performance. The significant reduction in the price target further emphasizes the bearish outlook, likely leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100